The drug company under fire for raising the price of an AIDS and cancer drug more than five-thousand percent is now facing and Antitrust probe. The New York State Attorney General is looking into whether Turing Pharmaceuticals is trying to prevent generic versions of DARAPRIM from being produced. DARAPRIM is used to treat parasitic infections, as well as patients with AIDS and cancer. Shortly after acquiring rights to the drug, Turing raised its price from just over $13 a tablet to $750 per pill. Generic drugs typically force companies to keep prices low. Turing recently pledged to lower the price of DARAPRIM after protests, but it has yet to do so.